The HEAL Italia Foundation is currently attending the international summit “Italy on the Move,” held in conjunction with the 44th J.P. Morgan Annual Healthcare Conference, one of the world’s preeminent forums for the healthcare, biotech, and investment sectors.
Organized by the Italian Trade Agency (ICE) in collaboration with the Ministry of Foreign Affairs and International Cooperation, the Ministry of Business and Made in Italy, the Consulate General of Italy in San Francisco, and Invest in Italy, the event brought together over 200 stakeholders and decision-makers from the Italian and U.S. biotech, pharmaceutical, and financial ecosystems. The summit aims to strengthen transatlantic dialogue regarding research, technological innovation, and strategic investment opportunities.
Market data confirms the strategic weight of the Italian sector: the Life Sciences industry in Italy generates a turnover exceeding €237 billion (nearly 10% of national GDP) and employs 1.8 million people (Source: Assolombarda-Confindustria/Istat). As of 2024, the biotech sector alone recorded a turnover of over €47.5 billion (2.23% of GDP), with R&D investments reaching approximately €2 billion.
Within the framework of bilateral economic relations, Italy invested $76.7 billion in the United States in 2024, while U.S. investment in Italy totaled $22.4 billion, underscoring the significant growth potential for further U.S. capital in the country (Source: Bank of Italy). The attraction of foreign direct investment (FDI) remains a core objective for the HEAL Italia Foundation, building upon the initiatives launched at BIO International in Boston last June. The goal is to capture North American opportunities in next-generation precision medicine technologies and services, integrating them into the foundation’s national service framework. Furthermore, the availability of substantial funding for research and innovation—specifically through the STEP (Strategic Technologies for Europe Platform) instruments implemented by several Italian regions—represents a major incentive for joint initiatives, several of which are already in the developmental phase.
In doing so, the Foundation consolidates its role as an Innovation Hub for Precision Medicine, serving as a catalyst for attracting new ideas and technologies to foster the development of advanced projects and health-biotech enterprises across the national territory.
